|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Answers:A model for watershed planning 显示文摘 | Beasley D B Huggins L F Monke E J | 1981 | Transaction of the ASCE1981，23，4： | 1 |
| 2 | Latest re- search and treatment of advanced-stage epithelial ovarian cancer显示文摘 | Coleman R L Monk B J Sood A K | 2013 | Nat Rev Clin Oneol2013，10，4： | 1 |
| 3 | Survival data from a phase II, open- label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer 显示文摘 | Monk B J Pandite LN | 2011 | J Clin Oncol2011，29，36： | 1 |
| 4 | Cervical cancer therapy: cur- rent, future and anti-angiogensis targeted treatment显示文摘 | Willmott L J Monk B J | 2009 | Expert Rev Anticancer Ther2009，9，7： | 1 |
| 5 | Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma显示文摘 | Tewari D Monk B J Hunter M | 2004 | Invest New Drugs2004，22，4： | 1 |
| 6 | Phase Ⅱ trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study显示文摘 | Burger RA Sill MW Monk B J | 2007 | J Clin Oncol2007，25，33： | 1 |
| 7 | A phase Ⅱ trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube 显示文摘 | Herzog TJ Monk B J Rose PG | 2014 | Gynecol Oncol2014，132，： | 1 |
| 8 | Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical pathologic analysis of a Gynecologic Oncology Group/ Southwest Oncology Group/Radiation Therapy Oncology Group trial 显示文摘 | MONK B J WANG J IM S | 2005 | Gynecol Oncol2005，96，3： | 1 |
| 9 | Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial 显示文摘 | Monk B J Poveda A Vergote I | 2014 | Lancet Oncol2014，15，8： | 1 |
| 10 | Answers: A model for watershed planning显示文摘 | Beasley D B Huggins L F Monke E J | 1980 | Transactions of the ASAE1980，23，4： | 1 |
| 11 | Wnt signaling in ovarian tumorigenesis 显示文摘 | Gatcliffe TA Monk B J Planutis K | 2008 | Int J Gynecol Cancer2008，18，5： | 1 |
| 12 | Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer 显示文摘 | Burger RA Monk B J Kurosaki T | 1996 | J Natl Cancer Inst1996，88，19： | 1 |
| 13 | Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women显示文摘 | Chan J K Lin Y K Monk B J | 2001 | Obstet Gynecol2001，97，5： | 1 |
| 14 | Recent achievements anti future develop- ments in advanced and recmTent cervical cancer: trials of the Gy- necologic Oneology Group 显示文摘 | Tewari K S Monk B J | 2009 | Semin 0ncol2009，36，2： | 1 |
| 15 | Wnt signaling in ovarian tumorigenesis显示文摘 | Gatcliffe T A Monk B J Planutis K Holcombe R F | 2008 | Int J Gynecol Cancer2008，18，： | 1 |
| 16 | Cervical cancer therapy: current, future and anti-angiogensis targeted treatment显示文摘 | Willmott L J Monk B J | 2009 | Expert Rev Anticancer Ther2009，9，7： | 1 |
| 17 | Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and ⅡA cervical carcinoma显示文摘 | Cha DS Walker JL | 1994 | Gynecol Oncol1994，54，1： | 1 |
| 18 | Adhesions after extensive gynecologic surgery: clinical significance, etiology, and preven- tion 显示文摘 | Monk B J Berman ML Montz FJ | 1994 | Am J Obstet Gynecol1994，170，51： | 1 |
| 19 | Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix:a gynecologic oncology group study 显示文摘 | Monk B J Sill MW Burger RA | 2009 | J Clin Oncol2009，27，7： | 1 |
| 20 | Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage Ib and II a Cervical carcinoma显示文摘 | Monk B J Cha DS Walker JK et oi | 1994 | Gynecol Onco11994，54，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员